Matrix metalloproteinase 9 expression: New regulatory elements

Journal of Ocular Biology, Diseases, and Informatics

Volumn 3, Issue 2, 2010, Pages 41-52

  Surgucheva, Irina ^a,b   Chidambaram, Kumaravel ^c   Willoughby, David A ^c   Surguchov, Andrei ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c Ocean Ridge Biosciences   (United States)

Author keywords

Extracellular matrix; Matrix metalloproteinases; MicroRNA; Retinal ganglion cells; Untranslated region

Indexed keywords

CIS ACTING ELEMENT; GELATINASE B; LUCIFERASE; MICRORNA; MICRORNA 340; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION REGULATION; GENE ISOLATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE;

EID: 79955841918     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-010-9054-2     Document Type: Article

References (43)

1. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989;107:186-8. (Pubitemid 19049847)
2. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33-44.
3. Kerrigan L, Zack D, Quigley H, et al. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-5. (Pubitemid 27328493)
4. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Investig Ophthalmol Vis Sci. 1995;36:774-86.
5. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-33.
6. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001;33:205-16. (Pubitemid 32219129)
7. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol. 2000;18:666-73. (Pubitemid 30327344)
8. Morgan JE. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye (Lond). 2000;14:437-44. (Pubitemid 30479745)
9. HernandezMR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000;19:297-321. (Pubitemid 30122725)
10. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem. 2002;277:47461-8. (Pubitemid 36159263)
11. Zhang X, Chintala SK. Influence of interleukin-1 beta induction and mitogen-activated protein kinase phosphorylation on optic nerve ligation-induced matrix metalloproteinase-9 activation in the retina. Exp Eye Res. 2004;78:849-60. (Pubitemid 38252961)
12. Manabe S, Gu Z, Lipton S. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Investig Ophthalmol Vis Sci. 2005;46:4747-53. (Pubitemid 44264580)
13. Cong Y, Guo X, Liu X, Cao D, Jia X, Xiao X, et al.Association of the single nucleotide polymorphisms in the extracellular matrix metalloprotease-9 gene with PACG in southern China. Mol Vis. 2009;15:1412-7.
14. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and iop-induced effects on extracellular matrix. Investig Ophthalmol Vis Sci. 2005;46:175-82. (Pubitemid 40041195)
15. Mozaffarieh M, Flammer J. Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol. 2007;52:S174-9. (Pubitemid 350060969)
16. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000;21:867-76. (Pubitemid 32209636)
17. Rivera S, Ogier C, Jourquin J, et al. Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci. 2002;15:19-32. (Pubitemid 35478006)
18. Vaillant C, Meissirel C, Mutin M, Belin MF, Lund LR, Thomasset N. MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol Cell Neurosci. 2003;24:395-408. (Pubitemid 37311303)
19. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol. 2007;152:189-205. (Pubitemid 47517601)
20. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm. doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells. Circulation. 2009;119:2209-16.
21. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, et al. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008;9:34-46. (Pubitemid 351266968)
22. Nothnick WB. Novel targets for the treatment of endometriosis. Expert Opin Ther Targets. 2004;8:459-71. (Pubitemid 39359651)
23. Geller HM, Dubois-Dalcq M. Antigenic and functional characterization of a rat central nervous system-derived cell line immortalized by a retroviral vector. J Cell Biol. 1988;107:1977-86. (Pubitemid 18263556)
24. Surgucheva I, Surguchov. ã-Synuclein: cell-type specific promoter activity and binding to transcription factors. J Mol Neurosci. 2008;35:267-71.
25. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res. 2006;33:7138-50.
26. Akool el S, Kleinert H, Hamada FM, Abdelwahab MH, Förstermann U, Pfeilschifter J, et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol. 2003;23:4901-16. (Pubitemid 36793336)
27. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. CombinatorialmicroRNA target predictions. Nat Genet. 2005;37:495-500.
28. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:D149-53. (Pubitemid 351149712)
29. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of micro-RNA-target recognition. PLoS Biol. 2005;3:e85.
30. Mali RS, Cheng M, Chintala SK. Intravitreous injection of a membrane depolarization agent causes retinal degeneration via matrix metalloproteinase-9. Investig Ophthalmol Vis Sci. 2005;46:2125-32.
31. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans. 2007;35:689-91. (Pubitemid 47310343)
32. Sivak JM, West-Mays JA, Yee A, Williams T, Fini ME. Transcription factors Pax6 and AP-2alpha interact to coordinate corneal epithelial repair by controlling expression of matrix metalloproteinase gelatinase B. Mol Cell Biol. 2004;24:245-57. (Pubitemid 38010051)
33. Eberhardt W, Doller A, Akool el S, Pfeilschifter J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114:56-73. (Pubitemid 46498160)
34. Fähling M, Steege A, Perlewitz A, Nafz B, Mrowka R, Persson PB, et al. Role of nucleolin in posttranscriptional control of MMP- 9 expression. Biochim Biophys Acta. 2005;1731:32-40. (Pubitemid 41463598)
35. Jespersen C, Doller A, Akool el-S, Bachmann M, Müller R, Gutwein P, et al. Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells. J Cell Physiol. 2009;219:276-87.
36. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007;13:333-46. (Pubitemid 46085282)
37. Seki M, Soussou W, Manabe S, Lipton SA. Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptor-mediated excitotoxicity. Investig Ophthalmol Vis Sci. 2010;51:1198-207.
38. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci. 2005;25:6401-8. (Pubitemid 40962536)
39. Makeyev EV, Maniatis T. Multilevel regulation of gene expression by microRNAs. Science. 2008;319:1789-90. (Pubitemid 351451555)
40. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 2008;105:5874-8. (Pubitemid 351758465)
41. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113:249-55.
42. Georgiadis A, Tschernutter M, Bainbridge JW, Robbie SJ, McIntosh J, Nathwani AC, et al. AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins. Gene Ther. 2010;17:486-93.
43. Luna C, LiG, Qiu J, Epstein DL,Gonzalez P. Role ofmiR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol Vis. 2009;15:2488-97.